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Background: Many patients with acromegaly do not achieve biochemical control with first-generation
somatostatin analogues. A large, multicenter, randomized, Phase III core study demonstrated that pasireotide LAR
had significantly superior efficacy over octreotide LAR. This analysis explores the efficacy and safety of switching
therapeutic arms in inadequately controlled patients during a 12-month crossover extension.
Methods: Patients with inadequate biochemical control (GH ≥2.5 μg/L and/or IGF-1 > ULN) at end of core study
(month 12) were eligible to switch to pasireotide LAR 40 mg/28 days (n = 81) or octreotide LAR 20 mg/28 days
(n = 38). One dose escalation to pasireotide LAR 60 mg/28 days or octreotide LAR 30 mg/28 days was permitted,
but not mandatory, at month 17 or 20.
Results: Twelve months after crossover, 17.3 % of pasireotide LAR and 0 % of octreotide LAR patients achieved
GH <2.5 μg/L and normal IGF-1 (main outcome measure); 27.2 and 5.3 % of pasireotide LAR and octreotide LAR
patients achieved normal IGF-1, respectively; 44.4 and 23.7 % of pasireotide LAR and octreotide LAR patients achieved
GH <2.5 μg/L, respectively. Mean (±SD) tumor volume further decreased from the end of the core study by 25 % (±25)
and 18 % (±28); 54.3 % of pasireotide LAR and 42.3 % of octreotide LAR patients achieved significant (≥20 %) tumor
volume reduction during the extension. The safety profile of pasireotide LAR was similar to that of octreotide LAR, with
the exception of the frequency and degree of hyperglycemia-related adverse events.
Conclusions: Pasireotide LAR is a promising treatment option for patients with acromegaly inadequately controlled
with the first-generation somatostatin analogue octreotide LAR.
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Acromegaly is a rare disorder most commonly caused by
prolonged secretion of excess growth hormone (GH) from
a pituitary adenoma. In the absence of adequate treat-
ment, acromegaly is associated with increased morbidity
and mortality [1, 2]. The goals of therapy are to control
the levels of both GH and insulin-like growth factor 1
(IGF-1), reduce and/or stabilize tumor size, preserve pitu-
itary function and prevent recurrence. A recent consensus
statement on the management of acromegaly advocates
reducing GH and IGF-1 levels to as close to normal as
possible (GH <1.0 μg/L [using an ultrasensitive assay] and
IGF-1 within the normal range for age and sex) [3, 4].
Earlier studies measuring GH by radioimmunoassay indi-
cated that suppression of random GH to <2.5 μg/L and
normalization of IGF-1 levels are associated with restor-
ation of mortality to that of a standard population [5].
Somatostatin analogues are the mainstay of medical
therapy for patients with acromegaly who have not
achieved biochemical control after transsphenoidal sur-
gery. They can also be used as first-line treatment when
the chance of surgical cure is low (invasive macroadeno-
mas), when surgery is contraindicated, or for patients who
refuse surgery [6]. However, many patients do not achieve
biochemical control with first-generation somatostatin an-
alogues [7–12]. In those patients who do not fully respond
to somatostatin analogue monotherapy, recent clinical
practice guidelines have advocated the addition of a dopa-
mine agonist (cabergoline) or a GH receptor antagonist
(pegvisomant) to somatostatin analogue treatment [13].
Pasireotide, a multireceptor-targeted somatostatin
analogue, was rationally designed with a broader soma-
tostatin receptor (SSTR) binding profile than first-
generation somatostatin analogues to achieve higher
response rates. In a large, randomized, double-blind, Phase
III trial (core phase of this study), pasireotide long-acting re-
lease (LAR) was significantly superior to octreotide LAR at
providing GH <2.5 μg/L and normal IGF-1 at month 12 in
medically naïve patients with acromegaly [14]. The exten-
sion phase described here allowed patients with inadequate
biochemical control at month 12 to switch treatment at
month 13 (ie from octreotide LAR to pasireotide LAR or
vice versa). This manuscript reports the efficacy and safety
results at the end of the crossover extension phase.
Methods
Extension study: patients could cross over or continue
This was a planned double-blind extension study to a 12-
month, randomized, double-blind, multicenter, Phase III
trial (the core study). In the core study, patients were ran-
domized to pasireotide LAR 40 mg every 28 days or octreo-
tide LAR 20 mg every 28 days. Titration to pasireotide LAR
60 mg or octreotide LAR 30 mg at month 3 or 7 was per-
mitted, but not mandatory, based on biochemical response.Dose decreases (pasireotide LAR 60 to 40 mg and 40 to
20 mg; octreotide LAR 30 to 20 mg and 20 to 10 mg) were
permitted for tolerability, as was an increase to the original
dose upon resolution. Patients who completed month 12 of
the core study could enroll either to continue receiving
their randomized therapy or to switch therapy, depending
on biochemical response, at the end of the core study:
 Patients with GH ≥2.5 μg/L and/or IGF-1 > ULN
(upper limit of normal; age and sex matched) could
switch treatment to either pasireotide LAR 40 mg
every 28 days or octreotide LAR 20 mg every 28 days
at month 13. After crossover, patients could receive
octreotide LAR for 12 months or pasireotide LAR
for as long as clinical benefit was obtained. Among
patients who crossed over, one dose escalation to
pasireotide LAR 60 mg every 28 days or octreotide
LAR 30 mg every 28 days was permitted, but not
mandatory, at month 17 or 20. The results from
these patients are reported in this manuscript.
 Patients with biochemical control (GH <2.5 μg/L
and IGF-1 ≤ULN) at month 12 could continue
receiving their randomized therapy. At the discretion
of the investigator, patients without biochemical
control but with clinical benefit derived from the
study drug could receive their randomized therapy
during the extension. Results from these patients are
reported in a separate manuscript [15].
The study was conducted in accordance with the
Declaration of Helsinki, and an independent ethics com-
mittee or institutional review board for each study site
approved the study protocol. See Additional file 1 for
further details. All patients provided written informed
consent to participate in the trial (trial identifier:
NCT00600886).
Crossover phase
Patients and endpoints
The core study enrolled adult patients with active acro-
megaly (GH >5 μg/L or lack of suppression of GH nadir
to <1 μg/L after oral glucose tolerance test, and IGF-1
above the age-adjusted ULN) who had never received
medical therapy for acromegaly. Patients were eligible to
enroll if they had undergone ≥1 pituitary surgery, or if
they were de novo because of refused pituitary surgery
or contraindication for surgery; patients were not eligible
to participate if they had undergone pituitary irradiation
within the last 10 years. The full entry criteria have been
described previously [14].
Main endpoints
The main endpoint of the crossover phase was the propor-
tion of patients with both GH <2.5 μg/L and normal IGF-1
Bronstein et al. BMC Endocrine Disorders  (2016) 16:16 Page 3 of 10for age and sex 12 months after switching medical therapy
because of inadequate biochemical control (GH ≥2.5 μg/L
and/or IGF-1 >ULN). GH levels were determined by a 2-h
five-point mean on the morning of study-drug injection.
IGF-1 sampling was performed immediately before study-
drug injection. See the Additional file 1 for further details.
Additional endpoints
Other endpoints included the proportion of patients
achieving GH <2.5 μg/L, the proportion of patients achiev-
ing normal IGF-1, changes from extension baseline (defined
as last assessment prior to crossover) in GH and IGF-1,
changes from extension baseline in tumor volume, changes
from extension baseline in signs and symptoms, and safety
after switching therapy. Gadolinium-enhanced pituitary
magnetic resonance imaging was performed at extension
baseline and 12 months after crossover and evaluated by a
central reader blinded to treatment. A pituitary tumor vol-
ume change of ≥20 % from extension baseline was consid-
ered significant. Tumor volume was calculated by hand
drawing around the tumor circumference in coronal cross-
sections, multiplying the area by slice thickness, and sum-
ming the resulting volumes across all slices containing
tumor. See the Additional file 1 for further details.
Five symptoms of acromegaly (headache, fatigue, per-
spiration, paresthesia and osteoarthralgia) were scored
from 0 (no symptom) to 4 (very severe). Health-related
quality of life (HRQoL) was assessed each month using
the AcroQoL questionnaire, which is a 22-item instru-
ment that results in scores ranging from 0 (worst
HRQoL) to 100 (best HRQoL) [16, 17].
Safety was assessed according to the National Cancer
Institute Common Terminology Criteria for Adverse
Events (CTCAE) version 3.0 [18] and consisted of: moni-
toring and recording of all adverse events (AEs); regular
monitoring of hematology, blood chemistry and urinalysis
parameters; performance of physical examinations; and
body weight measurements. Blood samples for laboratory
tests, including blood glucose measurements, were drawn
at each visit under fasted conditions before the morning
dose of study drug. AEs experienced after switching treat-
ments are reported and were classified as grade 1 (mild), 2
(moderate), 3 (severe), or 4 (life threatening or disabling).
End of study
The last assessment of GH, IGF-1 and tumor volume
before the end of the planned extension phase was per-
formed at month 25; therefore, efficacy data are reported
up to month 25. Safety data are presented for all patients
after crossover until month 26.
Statistical analyses
Descriptive summary statistics were provided for the
crossover data. No formal statistical tests were plannedto compare the treatment arms during the crossover
phase. The extension was not designed to determine a
difference in efficacy or safety outcomes between the
two groups. Results include all patients with available
data for a given measure. GH and IGF-1 samples were
considered missing if they were taken >35 days after
injection.
Protocol amendment
Prior to implementation of a protocol amendment, pa-
tients randomized to pasireotide LAR in the core study
did not have the option to switch to octreotide LAR at
month 13. Additionally, patients randomized to octreo-
tide LAR in the core study who achieved GH <2.5 μg/L
and IGF-1 ≤ULN at month 12 could not continue re-
ceiving octreotide LAR during the extension phase; these
patients were considered to have completed the study at
month 12 and were discontinued. The protocol amend-
ment allowed patients to receive octreotide LAR in the
extension phase as either continued or crossover ther-
apy. Patients who entered the extension phase after the
protocol amendment received treatment in a double-
blind manner (n = 205), while those who entered prior
to the amendment received unblinded pasireotide treat-
ment for the duration of the extension (n = 34). Thirty-
four patients entered the extension phase prior to the
protocol amendment. Of these patients, 15 continued to
receive their randomized treatment with pasireotide
LAR and 19 crossed over from octreotide LAR to pasir-
eotide LAR during the extension; the latter 19 patients
are included in this manuscript (Fig. 1).
Nineteen and 13 patients in the pasireotide LAR and
octreotide LAR arms, respectively, completed the core
study prior to the protocol amendment but did not enter
the extension phase. Based on manual review of the re-
sponse status for each patient at month 12, it is esti-
mated that 14 patients in the pasireotide LAR arm
would have potentially been eligible to cross over to
octreotide LAR during the extension phase had they
reached the end of the core study after implementation
of the amendment; four patients in the octreotide LAR
arm would have potentially been eligible to continue re-
ceiving octreotide LAR.
Results
Patient characteristics, disposition and exposure to
medication
In total, 358 patients entered the core study, and 141
(80.1 %) and 156 (85.7 %) pasireotide LAR and octreo-
tide LAR patients, respectively, completed 12 months of
treatment. The results of the core study have been de-
scribed elsewhere [14].
Of the 119 patients who switched therapy at month
13, 81 crossed over to pasireotide LAR and 38 crossed
Fig. 1 Patient disposition. Flowchart showing the number of
patients who were randomized, completed the 12-month core
study, entered the extension on their randomized treatment, and
entered the extension after switching to the opposite treatment.
Thirty-four patients entered the extension phase prior to implementation
of the protocol amendment and received unblinded treatment during
the extension; of these: *15 patients continued to receive their
randomized treatment with pasireotide LAR and †19 crossed over
from octreotide LAR to pasireotide LAR during the extension
Table 1 Demographics and characteristics at core study
baseline of patients who switched treatments
Demographic variable Crossed over to
pasireotide LAR
(N = 81)
Crossed over to
octreotide LAR
(N = 38)
Median age (range), years 45.0 (24–85) 48.5 (25–64)
Female, n (%) 38 (46.9) 22 (57.9)
Race, n (%)
Caucasian 42 (51.9) 20 (52.6)
Black 1 (1.2) 1 (2.6)
Asian 26 (32.1) 8 (21.1)
Native American 3 (3.7) 1 (2.6)
Other 9 (11.1) 8 (21.1)
Median time since diagnosis prior to
enrollment in the core study, months
7.1 4.2
Previous surgery, n (%) 35 (43.2) 10 (26.3)
Previous irradiation, n (%) 0 (0) 0 (0)
Median time since surgery prior to
enrollment in the core study, months
6.6 10.3
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extension, discontinuation rates were 38.3 % (n = 31/81)
and 34.2 % (n = 13/38) with pasireotide LAR and octreo-
tide LAR, respectively. Reasons for discontinuation in
the pasireotide LAR and octreotide LAR arms up to
month 12 of the crossover phase were AEs (12 and 1 pa-
tients, respectively), withdrawn consent (8 and 4 pa-
tients, respectively), unsatisfactory therapeutic effect (7
and 4), administrative problems (1 and 4), patient no
longer requires study drug (2 and 0), and abnormal
laboratory values (1 and 0). The median (range) duration
of treatment after crossover was 388 days (28–432) and
364 days (85–399) with a median of 14 and 13 injections
received for the pasireotide LAR and octreotide LAR
groups, respectively. Previous surgery (prior to enroll-
ment in the core study) had been performed in 43 %
(n = 35/81) and 26 % (n = 10/38) of patients switched to
pasireotide LAR and octreotide LAR, respectively
(Table 1); all remaining patients had not received any prior
treatment for acromegaly. None of the patients who en-
tered the crossover extension phase had previously re-
ceived pituitary irradiation.
At extension baseline, mean GH and IGF-1 levels were
5.9 μg/L and 1.9×ULN in patients who crossed over to
pasireotide LAR, and 7.1 μg/L and 2.1×ULN in patients
who crossed over to octreotide LAR. Some patients who
crossed over had control of either IGF-1 or GH at the
end of the core study. Among patients who crossed overto pasireotide LAR, 34 (42.0 %) had GH <2.5 μg/L but
not normal IGF-1 after 12 months of octreotide LAR
during the core study; four (4.9 %) had achieved normal
IGF-1 but not GH <2.5 μg/L. One patient who crossed
over to pasireotide LAR was biochemically controlled
(GH <2.5 μg/L and normal IGF-1) at month 12 of the
core study; this patient had elevated GH and IGF-1
levels 21 days after administration of the final dose of
octreotide LAR during the core study. Among the pa-
tients who crossed over to octreotide LAR, eight
(21.1 %) had GH <2.5 μg/L but not normal IGF-1 after
12 months of pasireotide LAR during the core study;
two (5.3 %) had normal IGF1 but not GH <2.5 μg/L. A
total of 69 (85.2 %) and 34 (89.5 %) patients who crossed
over to pasireotide LAR and octreotide LAR, respect-
ively, had been uptitrated during the core study.
Efficacy outcomes
Effect of treatment on GH and IGF-1 levels
Of the 81 patients inadequately controlled with octreotide
LAR who switched to pasireotide LAR, 14 (17.3 %; 95 %
CI: 9.8, 27.3) had biochemical control 12 months after
crossover. A total of 36 patients (44.4 %) had GH <2.5 μg/L
and 22 (27.2 %) had normal IGF-1 12 months after cross-
over. Of the 38 patients inadequately controlled with pasir-
eotide LAR who switched to octreotide LAR, none had
biochemical control 12 months after crossover. A total of
nine patients (23.7 %) had GH <2.5 μg/L and two (5.3 %)
had normal IGF-1 12 months after crossover (Table 2).
Twelve months after crossover to pasireotide LAR,
mean GH decreased to 2.5 μg/L (mean decrease of
23.7 %), and mean IGF-1 decreased to 1.1×ULN (mean
decrease of 39.9 %) (Fig. 2). Twelve months after
Table 2 Biochemical response rates at the end of the core study and after crossover, by treatment group
Crossed over to pasireotide LAR (N = 81) Crossed over to octreotide LAR (N = 38)
n (%) 95 % exact CI n (%) 95 % exact CI
GH <2.5 μg/L and normal IGF-1
End of core (month 12) 1 (1.2) (0.0–6.7) 0 (0.0) (0.0–9.3)
Month 3 14 (17.3) (9.8, 27.3) 1 (2.6) (0.1, 13.8)
Month 6 17 (21.0) (12.7, 31.5) 1 (2.6) (0.1, 13.8)
Month 9 18 (22.2) (13.7, 32.8) 2 (5.3) (0.6, 17.7)
Month 12 14 (17.3) (9.8, 27.3) 0 (0.0) –
GH <2.5 μg/L
End of core (month 12) 35 (43.2) (32.2–54.7) 8 (21.1) (9.6–37.3)
Month 3 40 (49.4) (38.1, 60.7) 11 (28.9) (15.4, 45.9)
Month 6 35 (43.2) (32.2, 54.7) 12 (31.6) (17.5, 48.7)
Month 9 44 (54.3) (42.9, 65.4) 12 (31.6) (17.5, 48.7)
Month 12 36 (44.4) (33.4, 55.9) 9 (23.7) (11.4, 40.2)
Normal IGF-1
End of core (month 12) 5 (6.2) (2.0–13.8) 2 (5.3) (0.6–17.7)
Month 3 16 (19.8) (11.7, 30.1) 3 (7.9) (1.7, 21.4)
Month 6 25 (30.9) (21.1, 42.1) 3 (7.9) (1.7, 21.4)
Month 9 24 (29.6) (20.0, 40.8) 4 (10.5) (2.9, 24.8)
Month 12 22 (27.2) (17.9, 38.2) 2 (5.3) (0.6, 17.7)
One patient who crossed over to pasireotide LAR had GH <2.5 μg/L and normal IGF-1 at month 12 of the core study; this patient had elevated GH and IGF-1 at last
assessment prior to the extension phase. CI confidence interval
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10.4 μg/L (mean increase of 74.5 %), and mean IGF-1
remained similar to baseline levels (mean increase of
15.9 %).
Evaluation of tumor response
In the core study, tumor volume decreased from base-
line by a mean (±SD) of 40 % (±22) and 38 % (±25) in
the pasireotide LAR and octreotide LAR groups, re-
spectively, and 81 and 77 % achieved significant (≥20 %)
tumor volume reduction. These results have been de-
scribed elsewhere [14]. Among evaluable patients who
entered the extension and crossed over to opposite treat-
ment, mean (±SD) tumor volume reduction from base-
line to month 12 during the core study (prior to
switching therapy) was 37 % (±21) in those randomized
to pasireotide LAR (n = 37) and 34 % (±23) in those ran-
domized to octreotide LAR (n = 69). After crossing over
to the opposite treatment arm, tumor volume decreased
further during the 12 months of the extension study by
a mean (±SD) of 25 % (±25) and 18 % (±28) with pasir-
eotide LAR (n = 46) and octreotide LAR (n = 26), re-
spectively. Significant tumor volume reduction from
extension baseline to month 12 after crossover was
achieved by 54.3 % (25/46) of pasireotide LAR patients
and 42.3 % (11/26) of octreotide LAR patients. Two pa-
tients in the pasireotide LAR group and one patient inthe octreotide LAR group had a ≥20 % increase in tumor
volume 12 months after crossover (Fig. 3).Effect on HRQoL and signs and symptoms
Mean [±SD] AcroQoL scores at extension baseline and
12 months after crossover remained similar in patients
who switched to pasireotide LAR (58.9 [±23.1] and 60.3
[±24.3]) and octreotide LAR (59.8 [±22.4] and 61.2
[±21.6]).
The severity of individual symptoms at core baseline was
similar for both treatment arms (range of mean values:
0.7–1.2 points in the pasireotide LAR group and 0.8–1.4
points in the octreotide LAR group). The five assessed
symptoms of acromegaly remained stable in both groups,
although slight improvements were seen in the pasireotide
LAR arm. Mean (±SD) changes from extension baseline to
12 months after crossover in the pasireotide LAR and
octreotide LAR arms were: headache −0.3 (±0.8) and 0.3
(±0.9); fatigue −0.1 (±0.9) and 0.0 (±0.9); perspiration 0.0
(±0.7) and 0.0 (±0.8); paresthesia −0.1 (±0.9) and 0.1
(±0.8); osteoarthralgia −0.1 (±0.6) and 0.1 (±0.6).Safety and tolerability
The safety profiles of both agents were similar to those
observed for the corresponding treatment in the core
study, that is, the safety profile of pasireotide LAR was
Fig. 3 Percentage change from extension baseline in tumor volume
12 months after crossover. Percentage change in tumor volume after
a switching to pasireotide LAR and b switching to octreotide LAR
Fig. 2 Mean a GH and b standardized IGF-1 levels at extension baseline
and after crossover. The n numbers refer to the number of patients
with available data at each month. Oct, octreotide; Pas, pasireotide;
SD, standard deviation
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quency and degree of hyperglycemia.
The most common AEs (pasireotide LAR and octreo-
tide LAR) regardless of a suspected study-drug relation-
ship were hyperglycemia (27.2 and 13.2 %), diarrhea
(22.2 and 18.4 %), cholelithiasis (18.5 and 15.8 %), head-
ache (19.8 and 13.2 %), diabetes mellitus (18.5 and
7.9 %), nasopharyngitis (14.8 and 18.4 %), and increased
blood creatine phosphokinase (7.4 and 15.8 %) (Table 3).
Six (7.4 %) patients in the pasireotide LAR group and six
(15.8 %) in the octreotide LAR group experienced ser-
ious AEs, of which two and one, respectively, were con-
sidered drug related.
When common AE terms were pooled, for example, all
terms relating to elevations in blood glucose, the most fre-
quently experienced AEs were hyperglycemia related (64.2
and 21.1 %), gallbladder and biliary related (25.9 and
21.1 %), and diarrhea related (22.2 and 18.4 %). Grade 3 or
4 hyperglycemia-related AEs were reported by 12.4 % of
patients in the pasireotide LAR group, compared with
none in the octreotide LAR group. Eleven (13.6 %) pa-
tients discontinued pasireotide LAR because of AEs (all of
these patients discontinued because of hyperglycemia-
related AEs); no patients discontinued octreotide LAR for
this reason. These included five cases of diabetes mellitusor type 2 diabetes mellitus and one case of diabetic
ketoacidosis.
Use of concomitant medication was similar between the
treatment groups, except for antidiabetic medication. Of
the 59 patients who did not have antidiabetic treatment at
extension baseline, 13 patients initiated antidiabetic medi-
cation after switching to pasireotide LAR. Of these, four,
seven and two patients required one, two or at least three
antidiabetic medications, respectively; the most commonly
administered antidiabetic drugs (≥3 patients) in these
Table 3 Adverse events regardless of study-drug relationship in ≥10 % of patients in either treatment group. Adverse events are
reported from extension baseline up to month 26
Crossed over to pasireotide LAR (N = 81) Crossed over to octreotide LAR (N = 38)
Adverse event All grades n (%) Grade 3/4 n (%) All grades n (%) Grade 3/4 n (%)
Total 75 (92.6) 19 (23.5) 34 (89.5) 8 (21.1)
Hyperglycemia 22 (27.2) 4 (4.9) 5 (13.2) 0
Diarrhea 18 (22.2) 0 7 (18.4) 1 (2.6)
Cholelithiasis 15 (18.5) 1 (1.2) 6 (15.8) 1 (2.6)
Headache 16 (19.8) 0 5 (13.2) 0
Diabetes mellitus 15 (18.5) 1 (1.2) 3 (7.9) 0
Nasopharyngitis 12 (14.8) 0 7 (18.4) 0
Arthralgia 10 (12.3) 0 2 (5.3) 0
Increased blood creatine phosphokinase 6 (7.4) 0 6 (15.8) 0
Dizziness 5 (6.2) 0 5 (13.2) 0
Increased blood triglycerides 1 (1.2) 0 4 (10.5) 1 (2.6)
AEs are reported according to terms used by the investigator. AEs are shown in descending order of frequency for patients who crossed over to pasireotide LAR
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peptidase 4 (DPP-4) inhibitors (n = 3), and metformin +
DPP-4 inhibitor (n = 3) [patients could be counted more
than once]. One patient initiated antidiabetic medication
with metformin after switching to octreotide LAR.
Mean fasting plasma glucose and glycated hemoglobin
(HbA1c) levels increased soon after switching from
octreotide LAR to pasireotide LAR; mean glucose and
HbA1c levels were 104 mg/dL and 6.19 % at extension
baseline, 130 mg/dL and 7.03 % at month 3, and
125 mg/dL and 6.68 % at month 12. By contrast, fasting
plasma glucose and HbA1c levels decreased to near
normal levels within 3 months after switching from
pasireotide LAR to octreotide LAR; mean glucose and
HbA1c levels were 127 mg/dL and 6.71 % at extension
baseline, 104 mg/dL and 6.12 % at month 3, and
103 mg/dL and 5.98 % at month 12.
Discussion
The results of this crossover extension period of a large
Phase III study showed that for patients who had inad-
equate biochemical control after 12 months of treatment
with octreotide LAR, 17.3 % (95 % CI: 9.8, 27.3)
achieved biochemical control 12 months after switching
treatment to pasireotide LAR. None of the patients who
switched from pasireotide LAR to octreotide LAR
achieved biochemical control 12 months after crossover.
These results suggest that pasireotide LAR may be a
promising therapeutic alternative in patients uncon-
trolled with octreotide LAR.
It is important to note that this extension phase was
not designed to detect statistically significant differences
between treatment groups. The crossover phase was
undertaken to provide additional information on the ef-
ficacy and safety of pasireotide LAR and to provideinsights into whether non-responders to octreotide LAR
or pasireotide LAR may benefit from switching to the
opposite therapy. The results reported here support the
findings from a recent 24-week, randomized, Phase III
study (PAOLA; NCT01137682), which was specifically
designed to evaluate the response to pasireotide LAR in
patients with acromegaly who were inadequately con-
trolled despite ≥6 months’ treatment with either octreo-
tide LAR or lanreotide Autogel. In this study, a
significantly higher proportion of patients achieved bio-
chemical control with pasireotide LAR versus continued
treatment with octreotide LAR or lanreotide Autogel at
week 24 (15.4 %/20.0 % versus 0 %; P = 0.0006 and
P < 0.0001, respectively) [19]. Given the rarity of acro-
megaly, few prospective trials have investigated the effi-
cacy and safety of medical therapies in a large number of
patients with acromegaly. The results from this cross-
over phase (N = 119) of a large Phase III trial provide a
valuable contribution to the existing literature.
In this Phase III study, biochemical control of acro-
megaly was defined according to targets recommended
by clinical consensus guidelines at the time of study ini-
tiation (GH <2.5 μg/L and normal IGF-1) [20]. More re-
cently, clinical practice guidelines have advocated
reducing GH levels to <1.0 μg/L (using a modern ultra-
sensitive assay) in the presence of normal IGF-1 levels
[13]. It is, therefore, possible that some patients who
were considered to be biochemically controlled in this
study may not have achieved the more stringent criteria
for biochemical control of acromegaly.
Pasireotide LAR is significantly (P = 0.007) superior to
octreotide LAR at providing GH <2.5 μg/L and normal
IGF-1 in patients who have not previously received medical
treatment for acromegaly, as shown in the core study. The
larger proportion of patients with biochemical control in
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IGF-1 normalization seen with pasireotide LAR (38.6 %
versus 23.6 %; P = 0.002) [14]. A similar finding was seen
12 months after switching treatments, with 27.2 % of pasir-
eotide LAR patients and 5.3 % of octreotide LAR patients
achieving normal IGF-1. This difference may be due to the
broader SSTR binding profile of pasireotide versus octreo-
tide LAR, coupled with the potential role of SSTRs in the
disruption of GH signaling on hepatic cells and, subse-
quently, IGF-1 transcription [21]. In rodents, activation of
hepatic SSTR2 and SSTR3 has been shown to downregu-
late IGF-1 transcription by inactivation of GH-induced sig-
nal transduction [21]. As pasireotide would bind with high
affinity to both SSTR2 and SSTR3 in the liver, the superior-
ity of pasireotide in normalizing IGF-1 levels may be ex-
plained by this proposed mechanism, although studies are
required to substantiate this suggestion. Receptor subtype
profiling to determine the relative expression of each SSTR
was not performed in the current study.
Interestingly, of the 81 patients who switched from
octreotide LAR to pasireotide LAR, 34 had GH <2.5 μg/L
(but not IGF-1 normalization) at month 12 of octreotide
LAR therapy, and 36 had GH <2.5 μg/L (with or without
IGF-1 normalization) 12 months after switching to pasir-
eotide LAR therapy. This finding is consistent with the
core study result that the two drugs have a similar effect
on GH, but that pasireotide LAR has a greater effect on
reducing IGF-1 levels. The similar SSTR2 binding affinity
of pasireotide and octreotide may be the mechanism
underlying these parallel GH findings and supports the
previously established finding that IGF-1 is the driver of
the superior efficacy of pasireotide LAR.
A few patients entered the crossover phase before a
protocol amendment was implemented; these patients re-
ceived open-label pasireotide LAR (n = 19) during the
crossover phase. As a result, there is a possibility of bias in
favor of pasireotide LAR for this small subset of patients.
Patients who completed the core study before the amend-
ment could not receive octreotide LAR in the extension
phase, either as continued therapy or by switching therapy;
this feature may have contributed to the imbalance in
crossover cohort numbers. Patient records were reviewed
retrospectively and it was estimated that 14 additional pa-
tients may have been eligible to cross over to octreotide
LAR if the protocol revision had been made earlier. It is un-
known if these patients would have entered the crossover
extension and/or achieved an improved response.
The crossover phase of this large Phase III trial provided
the opportunity to examine the safety profile of pasireo-
tide LAR and octreotide LAR after switching medical
therapies. After crossover, the safety profiles of pasireotide
LAR and octreotide LAR were similar to those seen in the
core study; pasireotide LAR has a similar safety profile to
that of octreotide LAR, except for a greater frequency anddegree of hyperglycemia-related AEs. This study suggests
that the hyperglycemia associated with pasireotide LAR is
reversible, as fasting plasma glucose and HbA1c levels
declined rapidly in patients who were switched from pasir-
eotide LAR to octreotide LAR. However, further investiga-
tion is needed to confirm this. It has recently been shown
in healthy volunteers that while pasireotide inhibits insulin
secretion and incretin response and suppresses glucagon
levels to a more modest degree, it does not affect insulin
sensitivity [22]. Patients receiving pasireotide treatment
should be closely monitored for changes in glucose
homeostasis, with antidiabetic medication initiated
promptly if hyperglycemia occurs. Based on the results of
mechanistic studies in healthy volunteers, a panel of ex-
perts have recently recommended that hyperglycemia as-
sociated with pasireotide in patients with Cushing’s
disease should be managed by the following staged in-
tensification of antidiabetic treatment until glycemic con-
trol is achieved: (i) initiation of metformin; (ii) addition of
a DPP-4 inhibitor; (iii) switch from the DPP-4 inhibitor to
a glucagon-like peptide 1 receptor agonist; (iv) initiation
of insulin therapy [23]. Given the relationship between
pasireotide and hyperglycemia, these recommendations
may also be applicable to patients with acromegaly.
Pegvisomant, a GH receptor antagonist, is currently
used in patients who have an inadequate response to max-
imal doses of somatostatin analogues [24]. Initial results of
pegvisomant in patients with acromegaly (n = 160) showed
that normal IGF-1 levels were achieved in 87 of the 90
(97 %) patients who received pegvisomant for at least
12 months [25]. Results from the ACROSTUDY registry
have demonstrated that pegvisomant, as either mono- or
combination therapy, provides IGF-1 normalization in
~63 % of patients after 5 years of treatment in clinical
practice [26]. However, in a recent study, combined treat-
ment with pegvisomant and long-acting somatostatin ana-
logues normalized IGF-1 levels in 97 % of patients who
were uncontrolled with somatostatin analogues alone [27].
Interestingly, in addition to its IGF-1-lowering effect, peg-
visomant may also improve glucose homeostasis in pa-
tients with diabetes mellitus [28]. However, pegvisomant
does not target the pituitary tumor and has no effect on
tumor volume. In the current study, tumor volume de-
creased further during the 12 months of the extension
study in both groups, with significant tumor volume re-
duction demonstrated in nearly half of all patients who
participated in the extension.
Conclusions
The results of this study, which support those from the
recent PAOLA study, suggest that pasireotide LAR may
be an effective treatment option in patients with acro-
megaly who are inadequately controlled with first-
generation somatostatin analogues.
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